Radioimmunotherapy with 90Y-ibritumomab tiuxetan is a safe and efficient treatment for patients with B-cell lymphoma relapsed after auto-SCT: an analysis of the international RIT-Network
- 27 September 2010
- journal article
- letter
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 46 (6) , 901-903
- https://doi.org/10.1038/bmt.2010.202
Abstract
No abstract availableKeywords
This publication has 7 references indexed in Scilit:
- Use of Radioimmunotherapy in Stem Cell Transplantation and Posttransplantation: Focus on Yttrium 90 Ibritumomab TiuxetanCurrent Stem Cell Research & Therapy, 2007
- Full-Dose 90Y Ibritumomab Tiuxetan Therapy Is Safe in Patients with Prior Myeloablative ChemotherapyClinical Cancer Research, 2005
- Phase I Trial of Iodine-131 Tositumomab With High-Dose Chemotherapy and Autologous Stem-Cell Transplantation for Relapsed Non-Hodgkin's LymphomaJournal of Clinical Oncology, 2005
- Treatment With Ibritumomab Tiuxetan Radioimmunotherapy in Patients With Rituximab-Refractory Follicular Non-Hodgkin’s LymphomaJournal of Clinical Oncology, 2002
- Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trialBlood, 2002
- Radioimmunotherapy with iodine 131I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experienceBlood, 2000
- Phase I/II Trial of IDEC-Y2B8 Radioimmunotherapy for Treatment of Relapsed or Refractory CD20+B-Cell Non-Hodgkin's LymphomaJournal of Clinical Oncology, 1999